WHO plans real-world pilot studies of GlaxoSmithKline’s malaria jab Mosquirix in three African countries.
Médecins Sans Frontières is empowering pharma investors to get involved in its fight to lower pneumococcal vaccine prices.
Today, RA studies are taking longer and require more sites to complete. With so few patients actually participating in clinical trials, what does the industry…
Bavarian Nordic has licensed a cell line from Valneva to help it manufacture vaccines based on its modified vaccinia Ankara vaccine platform.
Parents could be the next front in an ongoing effort by pharma companies and U.S. health officials to boost childhood immunization rates.
Vaccination rates among kindergarteners reached a record high in California after a tougher vaccine law went into effect.
Themis is the most recent company to usher a Zika vaccine to the clinic.
Sanofi Pasteur's dengue vaccine Dengvaxia will have to undergo phase 4 testing in Malaysia.
GlaxoSmithKline’s U.S. vaccine R&D head Ripley Ballou says emerging disease vaccine research needs a shakeup—and here's how.
Argentina's Sinergium Biotech, which is in a consortium to develop a Zika virus vaccine, intends to build a new plant that will use cell biology that can…
When Pfizer was gearing up to launch Prevnar 13 in adults age 50 and over, it faced a few unique challenges.